Head-to-head evidence
CG-0255 vs Vicagrel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: P2Y12 platelet receptor · full Atherosclerotic Cardiovascular Disease pipeline
CG-0255
Developed by Shanghai CureGene Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Vicagrel
Developed by Jiangsu Vcare Pharmaceutical Technology Co., Ltd.
NCT03599284 · Phase 2 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT06577519 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CG-0255's landscape · Vicagrel's landscape